$MLTX News

Moonlake Immunotherapeutics Inks Master Commercial Supply Agreement With Vetter Pharma To Manufacture One Or More Application Systems Pre-filled With An Active Pharmaceutical Ingredient, Placebo Or Other Material For Moonlake-8K

Needham Maintains Buy on MoonLake, Raises Price Target to $30

FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars

HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $45

Reported Sunday, MoonLake Secures FDA Alignment On Sonelokimab BLA Submission Plan, Holds $357.9M Cash With Runway Through End Of 2027

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares

How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa

MoonLake’s lead asset shows durability in late-stage HS studies

MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says

MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing

BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target

Reported Saturday, MoonLake's Phase 3 VELA Trials Show Sonelokimab Achieves 62% HiSCR75 And Up To 32% HiSCR100 At Week 40 In Moderate-To-Severe Hidradenitis Suppurativa

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Wolfe Research Upgrades MoonLake to Outperform, Raises Price Target to $24

Rothschild & Co Upgrades MoonLake to Buy, Raises Price Target to $40

Clear Street Maintains Buy on MoonLake, Raises Price Target to $70

Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update

RBC Capital Maintains Sector Perform on MoonLake, Raises Price Target to $13

HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $40

Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Share Price Performance And Premium P/B Ratio